17th Eemeli Workshop. Wednesday 13th August 2014 VTT, Micronova, Tietotie 3, Espoo. Juhani Luotola, Orion Diagnostica Oy

Transcription

1 17th Eemeli Workshop Wednesday 13th August 2014 VTT, Micronova, Tietotie 3, Espoo Juhani Luotola, Orion Diagnostica Oy Juhani Luotola / R&D 13/12/2014 1

2 2

3 Personalized Diagnostics and Care Personalized health care is a global trend, which creates plenty of new business opportunities An individualized health care is needed, so that eg. the most expensive treatments can be targeted to those who really will benefit from these treatments. The public sector has the main responsibility for the reforms, but this goal is realized only in broad cooperation with all sectors. This program allows the Finnish actors to be involved at the forefront in developing new operating models. Finnish health care infrastructure provides a good framework for the implementation of the program and for new ways of acting. The program is an excellent example of cooperation between different sectors of the society! 3

4 Personalized Diagnostics and Care The overall objective of the Personalized Diagnostics and Care program is to partially change health care priorities from waiting of symptoms towards early prevention of disease using personalized diagnostics and treatment. The program will also create new health care technologies and practices. Performing the research needed in the program would be completely impossible without the cooperation with major actors in the health sector. Extensive co-operation with all parties enables utilization of the genome information in clinical healthcare by an effective and responsible manner, taking also into account the sociological and socioeconomic aspects. The Academy of Finland program Personalised Health From genes to society is also complementing the whole. 4

5 For the first time in Finnish health and well-being area, "Personalized Diagnostics and Care" program will enable stakeholders in public and private health care, occupational health, multidisciplinary research and industry to build together new approaches for personalized diagnostics and care. GET IT DONE. Personalized Diagnostics and Care The overall objective of the program is to enhance the use of personalized medicine, especially personalized diagnostics and treatments. The program focuses on the efficient utilization of personal health records, patient records and genomic information including new technologies in point-of-care testing. The ICT solutions to be developed, including genetic and other laboratory data, support the effective use of patient data both in the prevention and care of diseases. - GET IT DONE. 5

6 The Consortium The consortium consists of 17 parties, 12 companies and 5 research organisations with 16 research groups in total. The participating companies: Labsystems Diagnostics Oy (earlier Ani Labsystems ALS), ArcDia International Oy Ltd, Carea Kymenlaakso Social and Health Services, Duodecim Medical Publications Ltd, Pharmaceutical Information Centre (LTK), HUS - The Hospital District of Helsinki and Uusimaa, Oy Medix Biochemica Ab, Mehiläinen Oy, Orion Diagnostica Oy (OD), Orion Pharma (OP), The Finnish Red Cross Blood Service (SPR) and United Medix Laboratories Ltd (YML). The research organisations: Aalto University, The Research Institute of the Finnish Economy - Etla, University of Helsinki (UH), University of Tampere (UTA), VTT Technical Research Centre of Finland. 6

7 Work Packages of Personalized Diagnostics and Care Program WP501 WP502 WP503 WP504 Infections, inflammation and enabling technologies for diagnostics and care Extracellular vesicles in health and disease Healthcare processes and electronic evidencebased decision support systems Genomics in chronic inflammation in Finland and Canada (CINFICA) Duration: Volume: 30 m Partners: 17 7

8 Responsibilities of work packages and budgeting Research Coordinator of the program since Aug 4 th 2014: Dr. Pirjo Wacklin, PhD, SalWe Oy 8

9 Infections, inflammation and enabling technologies for diagnostics and care (WP501) WP managers: Minna Mäki, Orion Diagnostica ja Harri Siitari, VTT WP501.1: Chronic inflammation and acute microbial infections in the gastrointestinal (GI) tract WP501.1A: Chronic inflammation in the GI tract WP501.1B: Acute microbial infections in the GI tract WP501.2: Diagnostics of acute respiratory tract infections WP501.2A: Novel diagnostic targets for group G and C streptocci WP501.2B: Novel diagnostic targets for viral respiratory tract infections WP501.3 Infections and inflammatory conditions during pregnancy and delivery WP501.3A: Novel diagnostic targets for early intra-amniotic infection WP501.3B: Novel diagnostic targets for Group B Streptococcus (GBS) and the GBS carrier state of the mother WP501.4: Integrated methods for sample preparation WP501.5A: One-step multiplex assay platform WP501.5B: Mobile POC technologies 9

10 Extracellular vesicles in health and disease (WP502) WP managers: Saara Laitinen, SPR Veripalvelu ja Elina Serkkola, Orion Pharma WP502.1: Extracellular vesicles in healthy donors - Blood based biomarkers WP502.2: Extracellular vesicles as a source of biomarkers for prostate cancer 10

11 Healthcare processes and electronic evidence-based decision support systems (WP 503) WP managers: Pasi Pöllänen, CAREA and Kimmo Pitkänen, HY FIMM WP503-1: Integrating Genetic Information and Electronic Clinical Decision Support WP503-2: Personalized medicine decision support system WP503-3: Immunogenetic profiling based on genome data WP503-4: Automatic decision support and supply-chain system in hospital services WP503-5: Usability, efficiency and cost-effectiveness of genomic data in the future health care: Sociological reflections WP503-6: Usability, efficiency and cost-effectiveness of genomic data in the future health care: Estimation of cost-effectiveness WP503-7a: A Business Model Perspective to Personalized Diagnostics and Care WP503-7b: Application of standardized impact and cost-benefit assessment tool in public-private partnership 11

12 Genomics in chronic inflammation in Finland and Canada (CINFICA) (WP504) WP managers: Jukka Partanen, SPR Veripalvelu and Päivi Saavalainen, HY WP504-1: Continuation of selected IMO biomarkers and platforms WP504-2: Novel genomic biomarkers WP504-3: Novel protein biomarkers WP504-4: Novel cell therapy 12

13 Goals of the program (1 ½ v) (1 ½ v) (1 v)

14 14